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TSLP Produced by Keratinocytes Promotes Allergen
Sensitization through Skin and Thereby Triggers
Atopic March in Mice
Juan Manuel Leyva-Castillo1, Pierre Hener1, Hua Jiang1 and Mei Li1
Atopic dermatitis often precedes the development of asthma, a phenomenon known as ‘‘atopic march’’.
An important role of allergen sensitization developed through barrier-defective skin has been recognized in the
onset of atopic march; however, the underlying mechanism remains poorly understood. In this study, we use an
experimental atopic march mouse model, in which the sensitization to allergen is achieved through barrier-
impaired skin, followed by allergen challenge in the airway. By using thymic stromal lymphopoietin (TSLP)iep/
mice in which the cytokine TSLP is selectively and inducibly ablated in epidermal keratinocytes, we demonstrate
that keratinocytic TSLP, the expression of which is induced by skin barrier impairment, is essential for
generating skin allergic inflammation and allergen-induced T helper type 2 response, for developing
sensitization to allergen, and for triggering a subsequent allergic asthma. Furthermore, using TSLPover mice in
which overexpression of keratinocytic TSLP is induced by skin topical application of MC903 (a vitamin D3
analog) in a dose-dependent manner, we show that keratinocytic TSLP levels are correlated with skin
sensitization strength and asthma severity. Taken together, our study uncovers a crucial role of keratinocytic
TSLP in the ‘‘atopic march’’ by promoting allergen sensitization occurring in barrier-impaired skin, which
ultimately leads to allergic asthma.
Journal of Investigative Dermatology (2013) 133, 154–163; doi:10.1038/jid.2012.239; published online 26 July 2012
INTRODUCTION
Atopic dermatitis (AD, eczema) frequently starts in early
infancy, and is characterized by skin inflammation and
impaired skin barrier function (Bieber, 2008; Boguniewicz
and Leung, 2011). More than 50% of AD patients with
moderate to severe AD develop asthma and/or allergic
rhinitis at a later stage, and the severity of AD appears to
influence the course of respiratory allergy. Although this
phenomenon is well known as the ‘‘atopic march’’ (Spergel
and Paller, 2003; Hahn and Bacharier, 2005; Boguniewicz
and Leung, 2011), how asthma progresses from AD still
remains obscure, and an effective prevention of the atopic
march is still lacking.
It has been recognized that, often during the course of AD, a
majority of patients develop sensitization to common food and/
or environmental allergens (Bieber, 2008; Cork et al., 2009;
Boguniewicz and Leung, 2011), and moreover that the severity
of AD correlates with the degree of sensitization and with the
risk of developing asthma (Schafer et al., 1999; Oettgen and
Geha, 2001). Indeed, allergen sensitization developed through
barrier-defective skin during AD could be a critical event
leading to subsequent allergic asthma (Bieber, 2008; Cork
et al., 2009; Benedetto et al., 2012); however, the mechanism
underlying skin sensitization is still poorly understood.
Thymic stromal lymphopoietin (TSLP) has emerged as a key
epithelium-derived cytokine in the AD pathogenesis (Liu,
2006; Ziegler and Artis, 2010). Increased expression of TSLP
has been revealed in skin keratinocytes from AD patients
(Soumelis et al., 2002), and elevated serum TSLP level was
reported in AD children (Lee et al., 2010a). Our previous study
(Li et al., 2005) and that of others (Yoo et al., 2005) have
demonstrated that transgenic mice overexpressing TSLP in
keratinocytes developed a spontaneous AD-like dermatitis.
We have further established an experimental TSLPover protocol
through which a skin topical application of MC903 (calcipo-
triol; a low-calcemic analog of vitamin D3) induces keratino-
cytic TSLP expression and triggers an AD-like syndrome
(Li et al., 2006, 2009). More recently, we reported that MC903
skin treatment aggravated experimental allergic asthma
induced by intraperitoneal (i.p.) sensitization to ovalbumin
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(OVA) and airway OVA challenge, which was mediated by
TSLP produced in keratinocytes (Zhang et al., 2009). Interest-
ingly, we also found that overexpressed keratinocytic TSLP
during the OVA sensitization phase was able to aggravate
OVA-induced asthma (Zhang et al., 2009). This study led us to
posit that TSLP overproduced in the skin of AD patients could
be a risk factor for the development of allergic airway
inflammation. A similar suggestion was made by Demehri
et al. (2009). However, in these previous experiments, allergen
sensitization was ‘‘artificially’’ achieved by i.p. injection of
OVA complexed with exogenous adjuvant (Takeda and
Gelfand, 2009; Holgate, 2011), which does not mimic the
sensitization occurring in epithelium sites such as skin (Bieber,
2008). In this study, by using an experimental ‘‘atopic march’’
mouse model, in which allergen sensitization is achieved
through barrier-impaired skin, followed by airway challenge,
our study demonstrates that keratinocyte-produced TSLP has
a crucial role in promoting allergen sensitization occurring
in skin, which ultimately triggers the ‘‘atopic march’’ leading
to allergic asthma.
RESULTS
An experimental ‘‘atopic march’’ model induced by OVA
epicutaneous (e.c.) sensitization through barrier-impaired
skin and intranasal (i.n.) challenge
We established a mouse model representing the atopic march
features (outlined in Figure 1a), which is initiated by an e.c.
sensitization phase by OVA treatment on barrier-impaired
skin through tape stripping (mimicking scratching in AD
patients) (Strid et al., 2004; Cork et al., 2009; Jin et al., 2009),
and followed by an OVA i.n. challenge phase. In this
model, e.c. OVA–treated wild-type Balb/c mice exhibited
an AD-like skin allergic inflammation (see Figure 2), and
developed an allergen sensitization evidenced by systemic
immune responses, including the production of OVA-specific
Igs (indicating an allergen-specific B-cell response), and
cytokine production of splenocyte cells upon in vitro OVA
stimulation (indicating an allergen-specific T-cell response;
see Figure 3). Upon i.n. challenge, these e.c. OVA–sensitized
mice exhibited an asthmatic phenotype (see Figure 4).
Barrier impairment induces TSLP production in keratinocytes
In skin extracts of nontreated (NT) wild-type Balb/c mice,
TSLP protein levels were undetectable by ELISA. In contrast,
upon phosphate-buffered saline (PBS) or OVA treatment on
barrier-impaired skin (e.c. PBS or e.c. OVA), TSLP protein
levels were upregulated after 3 hours, and further increased
9, 24, and 48 hours later (Figure 1b). These levels were not
significantly different between e.c. OVA and e.c. PBS
treatment, suggesting that TSLP induction was mainly due
to skin barrier impairment but not due to OVA application.
To examine whether epidermal keratinocytes were the
source of stripping-induced TSLP, we used TSLPiep/ mutant
(MT) mice, in which selective ablation of TSLP was induced
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Figure 1. Thymic stromal lymphopoietin (TSLP) production is induced in keratinocytes by tape stripping during epicutaneous (e.c.) sensitization in an
experimental mouse asthma model. (a) Experimental protocol. Dorsal skin of 10–12-week-old female mice was shaved and tape stripped (until TEWL
(transepidermal water loss) value reached 15–20 gm2 per hour) and treated with ovalbumin (OVA) every other day (D) from D0 to D10. Similar e.c. treatment
was repeated from D26 to D32. Nontreated (NT) mice or mice treated with phosphate-buffered saline (PBS) on tape-stripped skin (e.c. PBS) were used
as controls. Three weeks later, mice were intranasally (i.n.) challenged with OVA for 4 consecutive days (D50–D53). (b) TSLP protein levels in the skin of
wild-type Balb/c mice measured by ELISA at 3, 9, 24, and 48 hours after one e.c. PBS or e.c. OVA treatment. (c) TSLP protein levels measured by ELISA in
the skin of wild-type control (CT), TSLPiep/ (inducible ablation of TSLP in epidermal keratinocytes), and TSLPcep/ (constitutive ablation of TSLP in
epidermal keratinocytes) mice 48hours after one e.c. treatment. Values are mean±SEM (nX4 mice per group).
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at the adult stage in epidermal keratinocytes by tamoxifen
(Tam) treatment of K14-CreERT2/TSLPL2/L2 mice (Li et al.,
2009). The TSLP increase was nearly abolished in both e.c.
PBS– and e.c. OVA–treated TSLPiep/ mice (Figure 1c). The
residual induction of TSLP seen in e.c.-treated TSLPiep/
mice was most likely due to a o100% efficiency in Tam-
induced TSLP gene ablation in keratinocytes, as the induction
of TSLP was fully abolished in TSLPcep/ MT mice (K14-Cre/
TSLPL2/L2) (Li et al., 2009) in which the TSLP gene was
‘‘constitutively’’ ablated in keratinocytes at the embryonic
stage (Figure 1c). Therefore, barrier impairment by tape
stripping induces a production of TSLP in keratinocytes.
Ablation of TSLP in mouse skin keratinocytes results in a
reduced allergic inflammation upon e.c. OVA treatment
Wild-type control (CT; Tam-injected TSLPL2/L2 mice) and
TSLPiep/ MT mice were treated as described in Figure 1a.
At D12, e.c. OVA–treated CT mice exhibited epidermal
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Figure 2. Reduced allergic inflammatory infiltrate in skin of epicutaneous (e.c.) ovalbumin (OVA)–treated thymic stromal lymphopoietin (TSLP)iep/
mutant (MT) mice. (a) Hematoxylin and eosin (H&E) staining of skin paraffin sections from day (D)12, showing reduced epidermal thickening and dermal
infiltration in MT mice compared with wild-type control (CT) mice, upon e.c. OVA treatment. (b–d) Immunohistochemical (IHC) staining performed on
skin sections at D12, (b) with antibodies against CD4 (yellow corresponds to CD4þ staining and blue for DAPI staining of nuclei), (c) MBP (specific for
eosinophils; in dark red), or (d) Mcpt8 (specific for basophils; in dark red). (e) A summary of cell counts for skin-infiltrating immune cells at D12. Results
were obtained by calculating the average number of positively stained cells per microscopic field (at 200 magnification; nX12) **Po0.01; ***Po0.001.
Values are mean±SEM. (f) Comparison of H&E and IHC staining with antibodies against MBP or Mcpt8 in e.c.OVA–treated wild-type (WT) and Rag1/ skin
at D12. NT, nontreated; e.c. phosphate-buffered saline (PBS), treatment of PBS on tape-stripped skin; e.c. OVA, treatment of OVA on tape-stripped skin.
Bar¼50 mm.
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hyperplasia and dermal cell infiltration (Figure 2a). The
infiltrated cells comprised CD4þ cells (Figure 2b), eosino-
phils (Figure 2c), and basophils (Figure 2d), all of which are
characteristic cells in allergic skin inflammation (Leung et al.,
2004; Ito et al., 2011). This local skin infiltrate was not
seen in NT or e.c. PBS–treated CT skin (Figure 2a–e), indi-
cating that it was an immune response upon allergen
treatment on barrier-impaired skin, but was not induced by
barrier disruption alone. Notably, the infiltrate of eosinophils
and basophils was abolished in e.c. OVA–treated Rag1/
mice (Figure 2f), indicating that it was a T- and B-cell-
dependent, but not an innate inflammatory, response. Very
few CD8þ T cells or neutrophils were detected in e.c.-treated
CT skin (Figure 2e and data not shown). At D34, e.c.
OVA–treated CT mice showed an immune infiltrate similar
to that seen on D12 (data not shown).
In contrast, e.c. OVA–treated MT mice displayed a dras-
tically reduced skin allergic inflammation, exhibiting lesser
epidermal hyperplasia and dermal infiltrate of CD4þ cells,
eosinophils, and basophils at D12 (Figure 2a–e), as well as at
D34 (data not shown). Altogether, these results indicate that
keratinocytic TSLP is essential for generating skin allergic
inflammation upon OVA treatment on barrier-impaired skin.
The T helper type 2 (Th2) response induced by e.c. OVA
treatment is impaired in mice lacking TSLP in keratinocytes
When examined at D12, skin-draining lymph nodes (LN)
from the e.c. OVA–treated CT mice showed a significant
induction of IL-4, compared with NT or e.c. PBS–treated CT
mice (Figure 3a). This increase was abrogated in e.c.
OVA–treated TSLPiep/ MT mice (Figure 3a). In contrast,
the expression of Th1 cytokine (IFN-g) was not significantly
affected, whereas that of Th17 cytokine (IL-17A) was below
detectable levels (Figure 3a). Furthermore, we found that IL-4
expression was induced in purified CD4þ T cells from skin-
draining LNs of e.c. OVA–treated CT (Figure 3b), but not in
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Figure 3. Impaired T helper type 2 (Th2) cell response and defective allergen sensitization in epicutaneous (e.c.) ovalbumin (OVA)–treated thymic
stromal lymphopoietin (TSLP)iep/ mutant (MT) mice. (a, b) Quantitative reverse-transcriptase–PCR (RT-PCR) analyses of (a) skin-draining lymph nodes
(LN) and (b) purified CD4þ T cells from skin-draining LNs at day (D)12. (c) Quantitative RT-PCR analyses of purified CD11cþ dentritic cells (DCs) from
skin-draining LNs at D1. (d) Serum OVA–specific IgE, IgG1, and IgG2a levels at various time points (D12, D34, and D54). (e) Cytokine secretion by splenocytes
at D12, in response to in vitro OVA stimulation. *Po0.05; **Po0.01; ***Po0.001 (nX5 mice per group). Values are mean±SEM. CT, wild-type control
mice; NT, nontreated.
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Figure 4. An attenuated allergic asthma phenotype in epicutaneous (e.c.)-sensitized thymic stromal lymphopoietin (TSLP)iep/ mutant (MT) mice
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non-CD4þ T cells (data not shown), indicating that CD4þ
T cells were the major source of IL-4. This IL-4 induction
was clearly abolished in CD4þ T cells from e.c. OVA–-
treated MT mice (Figure 3b). Notably, even though tape
stripping on its own induced TSLP expression in keratino-
cytes of CT mice, it did not lead to IL-4 induction in CD4þ
T cells in the absence of OVA (compare CT_e.c.PBS with
CT_ e.c.OVA, Figure 3b).
It has been reported that dendritic cells (DCs) targeted
in vitro with TSLP express OX40L, which has been implicated
in the initiation of the Th2 cell response (Ito et al., 2005). The
expression of OX40L was therefore examined in purified DCs
from skin-draining LNs of CT and MT mice at D1 (i.e.,
24 hours after the first e.c. treatment), a time at which skin
DCs migrate to draining LNs after encountering an antigen
(Inoue et al., 2005). OX40L was induced in DCs from CT
mice upon e.c. OVA (but not upon e.c. PBS); however, this
induction was largely reduced in DCs from e.c. OVA–treated
MT mice (Figure 3c), indicating that keratinocytic TSLP was
required for OVA-induced OX40L expression in DCs. In
contrast, other costimulatory factors including CD40, CD86,
and CD80 were similarly increased in DCs from CT and MT
mice upon OVA treatment (Figure 3c and data not shown).
The expression of Th1-polarizing cytokine IL-12 was not
different between OVA-treated CT and MT (Figure 3c). Taken
together, these results indicate that keratinocytic TSLP has an
essential role in promoting e.c. OVA–induced Th2 response.
Allergen sensitization through skin is defective in mice lacking
TSLP in keratinocytes
To examine the sensitization to allergen, we first analyzed the
production of OVA-specific IgE, IgG1, and IgG2a. TSLPiep/
MT mice exhibited lower levels of OVA-specific IgE and
IgG1, whereas OVA-IgG2a levels were comparable in CT
and MT mice, after either e.c. sensitization (at D12 and D34)
or i.n. challenge (at D54; Figure 3d). We then analyzed
cytokine production by splenocytes upon in vitro OVA
stimulation. Th2 cytokine (IL-4, IL-13, and IL-5) levels were
all significantly reduced in MT mice at D12 (Figure 3e). A
decrease of IL-17 was also observed, whereas IFN-g levels
were comparable (Figure 3e). Similar results were obtained at
D34 (data not shown). Taken together, these data indicate
that keratinocytic TSLP is required for an optimal Th2
allergen sensitization through barrier-defective skin.
Allergic asthma induced by e.c. sensitization and airway
challenge is attenuated in mice lacking TSLP in keratinocytes
Upon i.n. OVA challenge, e.c. OVA–sensitized CT mice
(CT_e.c.OVA/i.n.OVA) exhibited an allergic airway inflam-
mation with peribronchiolar and perivascular infiltrates
(compared with CT_e.c.NT/i.n.OVA, Figure 4a), comprising
eosinophils (Figure 4c), basophils (Figure 4d), and CD4þ
T cells (data not shown). Very few CD8þ T cells or neutro-
phils were observed (data not shown). These mice also exhi-
bited hyperplasia of mucus-secreting goblet cells (Figure 4b).
Reverse-transcriptase–PCR analyses of lungs showed an
upregulated expression of Th2 cytokines (IL-4, IL-5, and
IL-13), Th2 chemokines (eotaxin-1, eotaxin-2, and MCP-2),
and CCR3 (mainly expressed by eosinophils and basophils),
whereas expression levels of IFN-g and IL-17A were not
significantly affected (Figure 4e). Whole-body plethysmogra-
phy analyses showed that these mice exhibited an enhanced
airway hyperresponsiveness (Figure 4f).
In contrast to CT mice, TSLPiep/ MT mice developed
an attenuated asthmatic phenotype upon e.c.OVA/i.n.OVA
treatment, as shown by much lesser infiltrates of eosino-
phils, basophils, and CD4þ cells (Figure 4a, c and d, and
data not shown), reduced goblet cell hyperplasia (Figure 4b),
decreased expression of Th2 cytokines and chemokines
(Figure 4e), and diminished airway hyperresponsiveness
(Figure 4f).
This attenuated asthmatic phenotype in MT mice was
due to defects in skin sensitization, but not due to airway
challenge, because TSLP was selectively ablated in skin
keratinocytes and not in airways (Li et al., 2009; data not
shown). Importantly, when sensitization was achieved
through i.p. route (by injection of OVA/alum), and followed
by i.n. OVA challenge, TSLPiep/ MT and CT mice deve-
loped a similar sensitization and asthmatic phenotype
(Supplementary Figure S1 online). Altogether, these data
demonstrate that keratinocytic TSLP is crucial for promoting
sensitization to allergen through skin, which triggers the
‘‘atopic march’’ and leads to allergic asthma.
Topical MC903 treatment induces keratinocytic TSLP
expression, enhances e.c. sensitization, and promotes allergic
asthma in a dose-dependent manner
It has been shown that TSLP is overexpressed in keratinocytes
in lesioned skin of AD patients (Soumelis et al., 2002).
To examine whether overproduction of TSLP could boost skin
sensitization, thus triggering the atopic march, keratinocytic
TSLP was induced by MC903 application during the first
phase of e.c. sensitization (Figure 5a). Note that upon MC903
treatment of wild-type Balb/c mice, TSLP expression was
rapidly induced in a dose-dependent manner (Figure 5b),
whereas ending the MC903 treatment normalized TSLP levels
within 3 days (Zhang et al., 2009; data not shown).
In e.c. OVA–treated TSLPover Balb/c mice, Th2 and Th17
(but not Th1) cytokines secreted by splenocytes at D34
were upregulated (Figure 5c), and serum OVA–specific IgE
and IgG1 were concomitantly increased (Figure 5d). It is
interesting to note that these enhancing effects of MC903
were clearly dose dependent.
Upon i.n. OVA challenge, MC903-treated e.c. OVA–
sensitized wild-type mice developed an aggravated asthmatic
phenotype. They exhibited enhanced mucus secretion and
increased airway inflammatory infiltrate comprising eosino-
phils, basophils, and CD3þ T lymphocytes (consisting
mainly of CD4þ but not CD8þ T cells; Figure 5e and f).
The aggravation of these asthmatic phenotypes was again
correlated with TSLP expression levels (Figure 5f). Accord-
ingly, mRNA levels of Th2 cytokines (e.g., IL-4, IL-5, and IL-
13), eosinophil-attractant chemokine (eotaxin-2) and receptor
(CCR3) in lungs, as well as in bronchoalveolar lavage cells,
were all dose-dependently increased (Figure 5g). Importantly,
in the absence of e.c. OVA sensitization, MC903-induced
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Figure 5. Skin topical application of MC903 induces keratinocytic thymic stromal lymphopoietin (TSLP) expression, enhances epicutaneous (e.c.)
sensitization, and promotes allergic asthma in a dose-dependent manner. (a) Experimental protocol. Eight to twelve-week-old female wild-type Balb/c
mice were subjected to the mouse model as described in Figure 1a, and concomitantly treated with MC903 or ethanol (EtOH) (its vehicle control) on the
same area of dorsal skin (DS), during the first phase of e.c. sensitization. (b) TSLP protein levels measured by ELISA at day (D)2 in dorsal skin upon topical
application of 0.08, 0.4, or 2 nmol MC903 at D 1 and D1. (c) Cytokine secretion by in vitro ovalbumin (OVA)–stimulated splenocytes from D34. (d) Serum
OVA–specific IgE, IgG1, and IgG2a levels at D12 and D34. Values are mean±SEM (nX6 per group). (e) Mucus production (periodic acid Schiff (PAS)
staining; in purple) and infiltrate of eosinophils (immunohistochemical (IHC) with MBP antibody) and basophils (IHC with Mcpt8 antibody) in lungs at D54.
(f) A summary of comparison of mucus production (PAS staining) and inflammatory infiltrates of various cells (by IHC) in lungs of e.c.-sensitized and
intranasal (i.n.)-challenged mice combined with different doses (0.08, 0.4, or 2 nmol) of MC903. Abundance of positive cells detected in lung sections
is presented with  (not detected) to þ þ þ þ (the most abundant). (g) Quantitative reverse-transcriptase–PCR (RT-PCR) analyses in mouse lungs
(left panel; values are mean±SEM; n¼ 6 mice per group) and bronchoaveolar lavage (BAL) cells (right panel; pool of six mice per group) at D54.
Results are representative of three independent experiments. b, bronchiole; NT, nontreated; v, vessel. Bar¼ 100mm.
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production of skin TSLP did not induce any asthmatic
phenotype upon OVA airway challenge (see e.c.NTþ2 nmol
MC/i.n.OVA; Figure 5f and g), indicating that the over-
produced skin TSLP on its own (without allergen) does not
promote asthma. Altogether, these data indicate that kerati-
nocytic TSLP expression level correlates with the strength of
skin sensitization and the severity of asthma.
DISCUSSION
An understanding of the mechanism of sensitization to
allergen through skin is crucial for elucidating the mechanism
underlying the ‘‘atopic march’’, and for possibly preventing
its development. In the present study, we demonstrate that
TSLP produced by keratinocytes is crucial for developing
allergen sensitization through barrier-impaired skin, and for
subsequent generation of allergic asthma.
The epidermis of AD patients is characterized by barrier
impairment, and the majority of the patients develop
sensitization to common allergens (Bieber, 2008; Cork
et al., 2009; Boguniewicz and Leung, 2011). We show that
impairing the mouse epidermal barrier through tape stripping
induces TSLP production in keratinocytes, in agreement
with a recent report (Oyoshi et al., 2010). Interestingly,
impairment of human skin barrier by tape stripping or by
application of sodium lauryl sulfate was also found to induce
epidermal TSLP expression (Angelova-Fischer et al., 2010).
Actually, various extrinsic or intrinsic factors have been
shown to impair the epidermal barrier, accompanied by TSLP
production in keratinocytes (Demehri et al., 2008; Briot et al.,
2009; Angelova-Fischer et al., 2010; Takai and Ikeda, 2011).
How these factors lead to TSLP expression remains to be
elucidated. The induction of TSLP by tape stripping does
not appear to involve the majority of TLR pathways, as
TSLP expression was similarly observed in tape-stripped
MyD88/ mouse skin (Supplementary Figure S2 online).
Whether it could be mediated via the proteinase-activated
receptor 2 (Briot et al., 2009; Lee et al., 2010b) needs to be
determined.
Our results demonstrate that keratinocytic TSLP induced
by barrier impairment is essential for generating a Th2
allergic immune response, as ablation of TSLP in keratino-
cytes leads to the abrogation of allergic skin inflammation
and Th2 response upon allergen treatment on barrier-
impaired skin (Figures 2 and 3). However, TSLP induced by
tape stripping does not on its own, in the absence of allergen,
lead to the skin recruitment of CD4þ cell, eosinophils, and
basophils (see Figure 2a–e). Similarly, it does not induce IL-4
(indicative of Th2 differentiation) in CD4þ T cells (Figure 3b),
nor does it induce OX40L (a key Th2 costimulatory factor) in
DCs (Figure 3c). These observations clearly suggest that TSLP
acts as a crucial Th2 ‘‘adjuvant’’ contributing to the allergic
immune response upon allergen treatment on barrier-
impaired skin. This conclusion differs from that drawn from
our own previous reports and that of others, showing that
transgenic TSLP (Li et al., 2005; Yoo et al., 2005) or MC903-
induced TSLP (Li et al., 2006, 2009) overexpression in mice
leads to a ‘‘spontaneous’’ AD, in the absence of allergen
treatment on skin. Indeed, in those previous mouse models,
TSLP expression was much higher: e.g., TSLP was detected in
a high level in serum (Li et al., 2005, 2006), whereas serum
TSLP was below detectable level (o7.8 pgml1) in the
present case. One possible explanation would be that above
a certain threshold level TSLP could trigger an immune
cascade even in the absence of penetration of any exogenous
allergens into the skin. Whether such a high TSLP level exists
in human AD patients is actually uncertain, but in any event
our present data demonstrate that a low level of TSLP
production is essential and sufficient for exerting its Th2
‘‘adjuvant’’ effect in promoting allergen sensitization through
barrier-impaired skin.
How mouse keratinocytic TSLP promotes the allergic Th2
response remains to be elucidated. Human TSLP has been
shown to target DCs in vitro to induce a Th2 response
(Soumelis et al., 2002; Ito et al., 2005; Liu et al., 2007), but
whether mouse TSLP exerts similar function was unclear
(Soumelis et al., 2002; Al-Shami et al., 2005; He et al., 2008).
We found that keratinocytic TSLP was essential for OX40L
expression in DCs in response to OVA, as early as 24 hours
after OVA encountering in barrier-defective mouse skin
(Figure 3c), suggesting that a TSLP (in keratinocytes)-OX40L
(in DCs) pathway could be critically involved in the initiation
of allergen-dependent Th2 response. In contrast to in vitro
studies (Al-Shami et al., 2005; Ito et al., 2005), we found that
e.c. OVA–induced expression of CD40, CD80, and CD86 in
DCs did not require TSLP (Figure 3c and data not shown).
Interestingly, a recent study has shown that the complete Th2
induction upon i.p. immunization of OVA plus adjuvant
(Nod1 or Nod2 agonists) was dependent on both TSLP
production in stromal cells and upregulation of OX40L on
DCs (Magalhaes et al., 2011). Therefore, a TSLP-OX40L axis
could be one common mechanism underlying Th2 priming
either through e.c. or i.p. route. In addition, we observed that
antigen presentation was impaired in TSLPiep/ MT mice
(Supplementary Figure S3 online). Which subset(s) of DCs in
the skin (Henri et al., 2010) is (are) possibly responsible for
the TSLP-promoted Th2 response to allergens and whether
TSLP may act on other antigen-presenting cells (e.g.,
basophils) (Maddur et al., 2010) to initiate the skin allergic
response remain to be investigated.
The impaired Th2 response in TSLPiep/ MT mice
correlates with defective skin sensitization and subsequent
asthma generation. Whereas OVA-induced IL-4 expression is
abolished in skin-draining LNs in these MT mice (Figure 3a),
OVA-specific IgE and IgG1, as well as OVA-stimulated Th2
cytokine production in splenocytes, were not fully abrogated
(Figure 3d and e), suggesting that factors (Cork et al., 2009)
other than TSLP also contribute to the complete Th2
sensitization to allergen in barrier-impaired skin. In contrast
to its effect on Th2 response, TSLP appears to have no or
a much less effect on the Th1 or Th17 response in skin
(Figure 3a). Accordingly, the expression of IFN-g or IL-17A
was not different in the lung upon OVA i.n. challenge
(Figure 4e). Moreover, neutrophils were barely detected in
the skin upon e.c. sensitization (Figure 2e), or in the lung
upon i.n. challenge (data not shown), in either CT or
TSLPiep/ MT mice.
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In contrast to TSLPiep/ MT mice in which skin sensiti-
zation is defective, TSLPover mice in which TSLP expression in
keratinocytes is induced by MC903 topical application
develop an enhanced e.c. sensitization and subsequently an
aggravated allergic asthma (Figure 5). It is interesting to note
that our data establish a significant correlation of skin TSLP
levels with sensitization strength, and with asthma severity,
further supporting the fact that keratinocytic TSLP represents
a risk factor for sensitization developed in AD patients and for
triggering the onset of the ‘‘atopic march’’.
In conclusion, our study has revealed that keratinocyte-
derived cytokine TSLP is crucial for promoting allergen
sensitization that occurs in barrier-impaired skin, which
accounts for the ‘‘atopic march’’ leading ultimately to allergic
asthma. It suggests that blocking TSLP production in skin
could be therapeutically useful in preventing or limiting
allergen sensitization that is commonly developed in AD
patients, and halting the progress of the ‘‘atopic march’’.
MATERIALS AND METHODS
Mice
Wild-type Balb/c and Rag1/ mice (in Balb/c background) were
purchased from Charles River Laboratories (Lyon, France). Eight to
twelve-week-old K14-Cre-ERT2(tg/0)/TSLPL2/L2 female mice (in a Balb/
c background) were injected i.p. with Tam (0.1mg in 100 ml
sunflower oil, for 5 consecutive days) (Li et al., 2000) to generate
TSLPiep/ mice. Tam-injected age- and sex-matched littermates
(K14-Cre-ERT2(0/0)/TSLPL2/L2) were used as CT. TSLPiep/ and CT
mice were subjected to experiments 4 weeks after the first Tam
injection. Breeding and maintenance of mice were performed under
institutional guidelines, and all of the experimental protocols were
approved by the Animal Care and Use Committee of the Institut de
Ge´ne´tique et de Biologie Mole´culaire et Cellulaire.
OVA e.c. sensitization and i.n. challenge
An area of approximately 2 cm2 of the dorsal skin of mice was
shaved and tape stripped until TEWL (transepidermal water
loss) measurement reached between 15 and 20 gm2 per hour
(DermaLab, Cortex Technology, Hadsund, Denmark), and then
treated with 200mg of OVA (Sigma, St Louis, MO) in 50ml PBS with a
cotton swab, every other day from D0 to D10. Similar e.c. treatment
was repeated for 4 times 2 weeks later from D26 to D32. NT mice or
mice treated with PBS on tape-stripped skin (e.c. PBS) were used as
controls. To induce an experimental asthma, mice were i.n. challenged
with OVA (50 mg in 25 ml saline) 3 weeks later, on 4 consecutive days
(D50 to D53). Airway reactivity was measured with whole-body
plethysmography (Emka Technologie, Paris, France) 1 day after the
last i.n. treatment before mice were killed for other analyses.
MC903 topical application
MC903 (calcipotriol; Leo Pharma, Ballerup, Denmark) was dissolved
in ethanol (Zhang et al., 2009) and topically applied on mouse
dorsal skin with the quantity indicated. Ethanol was used as vehicle
control.
Skin TSLP protein levels
Mouse skin was chopped and homogenized using Mixer Mill
MM301 (Retsch, Haan, Germany) in lysis buffer (25mM Tris, pH 7.8,
2mM EDTA, 1mM DTT, 10% glycerol, and 1% Triton X-100) supple-
mented with protease inhibitor cocktail (Roche). Protein concentra-
tion of skin extract was quantified using the Bio-Rad Protein Assay
(Bio-Rad, Marnes-la-Coquette, France). TSLP levels in skin extracts
were determined with the Duoset TSLP ELISA development kit (R&D,
Minneapolis, MN).
Antibodies
The following antibodies were used in the immunohistochemical
staining: rat anti-mouse MBP (provided by Dr James J Lee, Mayo
Clinic, Scottsdale, AZ), rat anti-mouse MCP-8 (clone TUG-8,
Biolegend, San Diego, CA), rat anti-mouse NIMP-R14 (Abcam,
Cambridge, MA), rat anti-mouse CD3 (clone 17A2, BD, Heidelberg,
Germany), rat anti-mouse CD4 (clone RM4-5, or clone GK1.5, BD)
and rat anti-mouse CD8 (clone 53-6.7, BD).
Splenocyte culture
Single-cell suspensions of spleen were cultured in medium (RPMI
1640 without HEPES supplemented by 10% FCS, 2mM glutamine,
100Uml1 penicillin, and 100mgml1 streptomycin) at a density of
2.5 106ml1 in the presence of 500mgml1 OVA in anti-CD3
(10 mgml1; clone 145-2C11 (e-Bioscience, Paris, France))- coated
96-well plates for 3 days. Cytokine levels of IL-4, IL-5, IL-13, IL-17,
and IFN-g in culture supernatants were measured using the Duoset
ELISA Development system (R&D).
Isolation of CD4þ T cells and DCs from mouse LNs
LN CD4þ T cells were purified using the mouse CD4þ T-cell
Isolation Kit II (Miltenyi Biotec, Paris, France; purity was confirmed
to 494%). LN CD11cþ DCs were first enriched using CD11c
Microbeads (Miltenyi Biotec) and then sorted with FACS Aria II (BD;
purity was confirmed to 495%).
Statistical analysis
Data were analyzed using SigmaStat (Systat Software, Richmond,
CA) by the Student’s t-test or the Mann–Whitney rank-sum
nonparametric test depending on results from the Kolmogorov–
Smirnov test (with Lilliefors’ correction) for normality and Levene
Median test for equal variance. Two-way repeated-measures
ANOVA was used to compare airway hyperresponsiveness between
groups responding to various doses of methacholine.
Other methods
Histopathology, immunohistochemical staining, serum Ig determi-
nation, quantitative reverse-transcriptase–PCR, and airway reactivity
were performed as previously described (Zhang et al., 2009; Hener
et al., 2011). Details of these methods, as well as in vivo proliferation
of the adoptively transferred T cell, can be found in the
Supplementary Materials and Methods online.
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